Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Sprintex has signed an exclusive distribution agreement with Washnah Trading Co. LLC for Saudi Arabia, giving the small-cap clean air technology group a formal channel into one of the world’s most infrastructure-hungry markets.

The agreement covers Sprintex’s G-Series, GA and GR high-speed Jet Blowers across the Kingdom. For investors, the headline number is not immediately huge, but it is tangible: once regulatory approvals are secured, Washnah must deliver minimum secured orders of US$500,000, or about A$701,000, for each 12-month period. Excess orders can be carried forward, which gives the arrangement some flexibility if demand arrives in lumps rather than neat annual parcels.

The initial term runs to 31 March 2029, with a two-year extension available if milestones are met. These milestones include vendor registration with Saudi Arabia’s National Water Company and product approvals via the SABER platform, part of the Saudi Standards, Metrology and Quality Organisation system.

That sounds like regulatory plumbing, and it is. But for industrial equipment suppliers, particularly those selling into government-linked water and wastewater projects, being on the approved vendor list is often the difference between watching the feast and getting a seat at the table.

Airport tender could be the company maker

The sizzle is Washnah’s tender for wastewater treatment works at King Salman International Airport, where Sprintex’s high-speed turbo blowers have been specified exclusively.

The tender includes about 30 Sprintex units ranging from 11 kW to 675 kW, covering process stages such as grease and grit removal, aeration tanks, membrane bioreactor tanks, sludge holding tanks and equalisation tanks. The package also includes acoustic enclosures, control panels with variable frequency drives and program logic controllers, IoT monitoring and commissioning support from Sprintex engineers.

Sprintex puts the potential opportunity at more than A$5 million, based on supply of blower content only. Tender award is expected in the second half of calendar 2026.

For context, Sprintex is a company with a market value of about A$52 million on ASX data and its shares were recently around 7.4 cents, according to market data. That means a single A$5 million equipment opportunity is not pocket change for the company, even allowing for the obvious caveat that a tender is not a purchase order.

Why the airport matters

King Salman International Airport is no ordinary terminal upgrade with new carpet and a brighter duty-free section. The project, based in Riyadh and owned by Saudi Arabia’s Public Investment Fund, is expected to cover 57 square kilometres and include six parallel runways. The airport is targeting capacity of up to 100 million passengers by 2030 and 185 million by 2050.

The official airport site says the development will include six runways, six terminals, a royal terminal, private aviation facilities, a cargo and logistics hub and real estate areas. It is designed as a core plank in Saudi Arabia’s push to turn Riyadh into a global hub for business, tourism and logistics.

For Sprintex, the attractive part is less glamorous than the architecture but arguably more dependable: wastewater treatment. Airports, cities, desalination plants and industrial facilities need continuous-duty systems. In these applications, energy efficiency is not green window dressing - it goes straight to operating costs.

Management talks scale and validation

Sprintex managing director and chief executive Jay Upton described the Saudi agreement and airport tender as “a significant milestone” in the company’s international expansion.

“The scale of the tender - approximately 30 high-power turbo blowers up to 675 kW across the full wastewater treatment works - provides powerful early validation of both our technology platform and the strength of the partnership,” Upton said.

He added that Saudi Vision 2030’s infrastructure programme creates a long-term opportunity for Sprintex’s energy-efficient blower solutions.

That is the nub of the investment case. Sprintex has been repositioning from its better-known automotive supercharger heritage toward industrial clean air applications, including wastewater, aquaculture, paper milling, pharmaceuticals and clean energy compressors. The Saudi deal gives it a local partner, a defined market and a flagship project to chase.

What investors should watch next

The next milestones are clear enough: Saudi regulatory approvals, National Water Company vendor registration, conversion of the airport tender into an awarded contract and evidence that Washnah can build a recurring pipeline beyond the glamour project.

The risk is equally clear. The A$5 million tender remains contingent, and large infrastructure projects can move with all the speed of a camel in a sandstorm when procurement, approvals and government priorities are involved. Minimum annual orders only kick in after approvals, so investors should be careful not to bank the revenue before the paperwork lands.

Still, for a sub-A$100 million ASX industrial technology stock, this is a credible door-opener. Sprintex now has exclusivity in Saudi Arabia, a local partner with wastewater sector relationships, minimum order commitments and a tender tied to one of the Middle East’s highest-profile infrastructure builds.

The runway is long, but at least Sprintex has found a gate.

Swift TV Ltd has given small-cap investors something more tangible than the usual tech-sector promise jar: installed hardware, contracted sites and a near-term deployment timetable. The company says 2,758 Swift TV screens have been installed across seven customer sites in just seven weeks, spanning resources and aged care customers, including global oil and gas operators and leading aged care providers. A further eight sites are scheduled for completion by 1 June 2026.

That matters because Swift has been trying to shift the investor conversation from “product development” to “commercial rollout”. In microcap tech, that transition is often where the wheels either start turning or fall off entirely. Swift is now arguing the former.

Recurring revenue is the prize

The key phrase for investors is recurring subscription revenue. Swift says revenue commences or expands as each site is commissioned, with deployments typically supported by multi-year contracts. That is a more attractive model than lumpy hardware sales, assuming the company can keep installation costs, support costs and churn under control.

The company does not provide contract values, average revenue per screen, gross margins or payback periods, so investors are still being asked to fill in a fair few blanks. But the operational metric is worth watching: 2,758 screens in seven weeks suggests the rollout process is no longer a lab exercise.

Chief executive Brian Mangano put it plainly, saying: “The speed of deployment we are seeing is a strong validation of the Swift TV platform and marks a clear transition from product development to commercial rollout.” He added that installing more than 2,700 screens in seven weeks showed the company’s ability to scale across multiple sites and that Swift is focused on converting deployments into recurring subscription revenue.

The 5,000-unit order is a confidence signal - with a caveat

Swift has also ordered another 5,000 units from a Google certified supplier to support its near-term pipeline. On one hand, that is a useful sign that management sees enough contracted or prospective demand to warrant inventory build-up. On the other hand, investors should watch the balance sheet implications.

Hardware orders cost money before revenue arrives. The company has not disclosed the unit cost, payment terms or whether customer contracts carry upfront contributions. For a company of Swift’s size, execution is not just about selling screens - it is about funding the rollout without squeezing working capital too hard.

At the time of writing, ASX data showed Swift shares at $0.009, with a market capitalisation of about $11.25 million. That valuation leaves little room for heroic assumptions, but it also means any credible growth in contracted recurring revenue could become material.

Why mining camps and aged care make sense

Swift’s chosen sectors are not random. Mining, oil and gas, aged care and hospitality all involve residents, workers or guests spending extended time in managed accommodation. That creates a natural use case for in-room entertainment, communications, messaging and engagement tools.

For resources customers, the attraction is likely to be workforce engagement and site communications, especially in remote camps where amenity can help with retention. For aged care operators, the platform may help with resident entertainment, family engagement and facility communications. Swift describes its product as an all-in-one connected TV platform designed to unify entertainment, communication and engagement, with integrations aimed at improving business outcomes.

The strategic logic is tidy enough. The investor question is whether Swift can turn that logic into scalable margins.

The next milestones

There are three things investors should watch from here. First, whether the eight additional sites due by 1 June are completed on schedule. Second, whether Swift starts providing harder revenue metrics, such as annualised recurring revenue, revenue per screen, contract length and gross margin. Third, whether the 5,000-unit order translates into commissioned sites rather than sitting in inventory like a very modern-looking Christmas tree pile.

Swift has not yet given the market the full economics of the rollout. But it has provided a clearer operational scoreboard. Screens are being installed, customers are being commissioned and the company says recurring revenue is now beginning to flow or expand as sites go live.

For a sub-$15 million ASX technology company, that is a meaningful step. The next job is to prove that scale can come with cash flow, not just more screens on walls.

Adisyn has moved quickly to turn a burst of technical and strategic momentum into cash, lining up a placement of up to 207.4 million shares at 6.75 cents each, which works out to about $14 million before costs. Of that total, 204.4 million shares can be issued under the company’s existing placement capacity, while a further 2.96 million shares for director participation remain subject to shareholder approval. The proposed issue date for the main tranche is 30 April 2026, with the director component to be put to holders on 11 June 2026.

For existing investors, the first point is that this is not a token top-up. It is a meaningful capital raising that will expand the register and reshape the balance sheet. Using ASX’s quoted market capitalisation of $61.72 million and a last price of 7.5 cents, the placement equates to roughly one new share for every four already on issue - a dilution event of about 25%. That is not trivial, but neither is the cheque being written. In small-cap land, a raise of this size usually tells you one of two things: the company is plugging a hole, or institutions think there is enough in the story to fund the next leg properly. Adisyn is clearly pitching the latter.

Institutions are not just turning up - they are cornerstoning it

What lifts this above the run-of-the-mill placement is the identity of the backers. The company says the raising was cornerstoned by Regal Funds Management and Meitav, described as Israel’s largest investment house. That matters because institutional names can act as a form of external validation, particularly for a company whose appeal rests on commercialising advanced materials rather than churning out near-term cash flow. The placement was also led by Sandton Capital Advisory, which will receive a 6% fee, and the director participation totals about $200,000, subject to approval.

The price itself was not especially punitive by small-cap standards. Adisyn says the 6.75 cent issue price represents a 10% discount to the last closing price of 7.0 cents on 21 April 2026 and a 5.78% discount to the 15-day VWAP. In other words, the company raised serious money without having to serve up a bargain-bin special. That suggests the book was supported by investors willing to pay close to market for exposure to the story, which is often a better sign than a deeply discounted rescue mission.

Why the market was prepared to stump up

The timing is no accident. Adisyn has just come off the back of two eye-catching developments. First, it reported a low-temperature graphene deposition result using an industrial atomic layer deposition system, which the company argues is an important step toward semiconductor interconnect applications. Second, it secured exclusive worldwide rights from Tel Aviv University’s commercialisation arm to graphene-based radar absorption technology aimed at defence and drone applications. Together, the pair broaden the investment case from pure lab promise to something closer to a platform story with semiconductor and defence angles.

That does not mean the technology risk has vanished. Far from it. Graphene has a long and colourful history of exciting presentations and limited commercial payoff. What Adisyn has done, though, is give investors two reasons to believe the company may have edged closer to a real addressable market. The semiconductor result goes to manufacturability and process compatibility, while the radar-absorbing materials deal points to a separate, defence-flavoured commercial pathway. When a company can pitch two potentially valuable verticals at once, it tends to get a better hearing from institutions.

What to watch next

The near-term checklist is straightforward. Investors will want to see the main tranche settle and allot on schedule, director participation approved, and - most importantly - evidence that the fresh cash is producing commercial progress rather than just extending the corporate runway. The funds are earmarked for graphene technology programs, business development, working capital and offer costs. That is sensible enough, but broad enough that management now needs to show tangible milestones. A bigger register and a fatter bank account buy time. They do not buy forgiveness forever.

Adisyn has taken a meaningful step in turning a promising materials story into something semiconductor companies might eventually take seriously. The company says it has demonstrated continuous graphene formation on a 1cm x 1cm copper coupon using an industrial atomic layer deposition, or ALD, system, with the process running below the semiconductor sector’s approximate 450C thermal ceiling.

For investors, the key point is not simply that graphene was formed. Graphene has long been touted as a wonder material for chips because of its electrical and thermal properties. The rub has been manufacturing. Semiconductor makers do not like scientific miracles that only work in exotic lab conditions, at heroic temperatures, or with processes that require a factory reset of their production lines. Adisyn’s claim is important because it brings together three things the market wanted to see in the same sentence - graphene, industrial equipment, and semiconductor-compatible temperatures.

That does not make Adisyn a chip industry kingmaker overnight. But it does move the conversation from "interesting science" towards "possibly relevant process technology".

Why copper is the problem child

Adisyn is targeting one of the semiconductor industry’s sore spots: copper interconnects. These are the microscopic wiring systems that link billions of transistors on advanced chips. As geometries shrink, copper becomes more troublesome, with higher resistance, more heat, and more power loss. That in turn threatens performance, efficiency and the industry’s long-running obsession with cramming ever more capability into ever-smaller devices.

If Adisyn’s process can eventually help graphene replace or augment copper in advanced interconnects, the commercial addressable market could be very large. The company is clearly pitching this toward high-value chip segments such as AI processors, GPUs, CPUs, advanced mobile devices and networking hardware. That is the glamour end of semis, where performance gains are prized and bottlenecks matter.

For small-cap investors, that is the allure. Adisyn is not chasing a niche coating application with modest upside. It is trying to insert itself into one of the most strategically important parts of the global semiconductor stack.

The real achievement is process compatibility

What gives this update more weight than the average frontier-tech flourish is the emphasis on industrial compatibility. The work was carried out through subsidiary 2D Generation using a standard industrial ALD system and Adisyn’s patented ALD methodology and precursor chemistry. In plain English, the company is saying its graphene is being made with tools and conditions that resemble the real world of chip fabrication, rather than a one-off bench-top stunt.

Characterisation work using transmission electron microscopy and Raman spectroscopy confirmed continuous graphene layers across the full coupon area, with the cross-section indicating a layer thickness of about 1 nanometre. Continuity matters because interconnect materials cannot afford gaps, inconsistencies or reliability headaches. A discontinuous film may excite scientists, but it will not excite a wafer fab manager.

Chairman Kevin Crofton’s comments were revealing in that regard. He framed the result not as mission accomplished, but as the first step in making graphene relevant from a manufacturing perspective and in addressing one of the sector’s major performance constraints. That is the right tone. The market has seen enough moonshot materials stories to know there is a canyon between proof-of-concept and production adoption.

What comes next, and where the risk still sits

The next stage is less glamorous and probably more important. Adisyn says it will now focus on recipe optimisation, repeatability testing and scaling from coupon-level substrates to wafer-level formats, while also beginning commercial engagement with industry participants.

That is where the hard yards begin. Investors should watch for evidence that the company can reproduce the result consistently, improve film quality, and maintain performance as the substrate size increases. Semiconductor customers care about repeatability, yield, integration and reliability every bit as much as raw material promise. One good result opens the door. A repeatable process is what gets you invited inside.

Commercial discussions with Tier 1 semiconductor groups would also be a useful signal, but they should be treated as a starting pistol rather than a finish line. Collaboration agreements, validation programs and technical engagement sound impressive, yet they do not guarantee revenue or adoption. In deep tech, the time between scientific validation and meaningful commercial returns can be measured in years, not quarters.

The investor takeaway

For Adisyn, this is a credible technical milestone with genuine strategic relevance. It appears to address a long-recognised semiconductor problem using a process that, at least at this early stage, fits more neatly within existing fabrication constraints than many graphene concepts have managed.

The company is still firmly in speculative territory, because scale-up, repeatability and industry qualification remain to be proven. But for investors willing to follow early-stage advanced materials stories, this result strengthens the thesis that Adisyn may have something more substantial than a glossy graphene dream. The company has not yet solved the interconnect dilemma. It has, however, shown that its technology may deserve a place in the conversation.

For long-suffering Memphasys investors, the March quarter offered something rarer than biotech promise - actual customer receipts. The reproductive biotech minnow says quarterly revenue topped $100,000, repeat cartridge orders are now coming through from multiple regions, and more than $1.4 million of multi-year contracted revenue has been secured across Europe and MENA. That marks a notable change in tone for a company that, until recently, was still largely selling the commercial dream of its Felix sperm selection system rather than the product itself.

From science story to sales story

Management is pitching the quarter as proof that its strategic reset late last year is working. The company narrowed its focus to Felix, shifted from a research-led model to commercial execution, set up a commercialisation committee and tightened the cost base. On the numbers presented, that reset is starting to show up where it matters most - revenue, repeat usage and regulatory clearances.

The key point for investors is not just the $106,000 of customer receipts for the quarter, but the nature of those receipts. Memphasys says revenue came from Europe, MENA and Japan, and that repeat cartridge orders are now emerging from existing customers. For a medical device company built around a consumables model, that is the difference between a one-off placement and the early signs of a recurring revenue stream.

Chairman Lindley Edwards put it plainly, saying the company is "no longer a development-stage organisation - it is now generating revenue from commercial sales" of Felix. That is a strong claim, but not an unreasonable one given the first meaningful receipts and the evidence of repeat ordering.

Europe and MENA are doing the heavy lifting

Geographically, Europe looks set to be the main engine room. CE Mark approval and UK CE MDR access open up the company's biggest near-term addressable market, and Italy appears to be the initial beachhead. Management says it is also expanding the broader European pipeline and adding commercial personnel on the ground to improve clinic engagement and conversion.

MENA is shaping up as the second leg of the stool. Clinical use continued in Qatar, repeat cartridge orders were received, and additional orders were secured across the UAE and Iraq. The company is also pushing regulatory and commercial pathways in Egypt and Turkey.

Japan remains smaller but strategically useful, providing another commercial reference point. India is the obvious wildcard. The regulatory submission has been lodged with the CDSCO, and Memphasys says it already has a contracted partner waiting for activation once approval comes through. If that approval lands around mid-2026 as hoped, India could move from PowerPoint opportunity to real contributor.

The real attraction is the consumables model

Investors should remember that Felix is not just about selling a machine into IVF clinics. The larger commercial prize lies in recurring cartridge sales tied to procedure volumes. Memphasys says clinics already using the system are re-ordering cartridges, which suggests Felix is moving beyond evaluation and into workflow integration.

That matters because medical device stories often live or die on utilisation, not installation. A clinic that buys a system but leaves it in the cupboard is worthless. A clinic that incorporates it into routine practice becomes an annuity stream. Memphasys is clearly trying to show the market that it is edging into the second category.

The balance sheet still keeps everyone honest

Before anyone gets carried away, the Appendix 4C is the necessary cold shower. Net operating cash outflow for the quarter was $724,000. Cash at quarter end stood at $420,000, which the company calculates as just 0.58 quarters of funding at the current burn rate. That is thin by any standard.

Yes, the company raised $800,000 in February, with $824,000 of equity proceeds recorded in the quarter before costs. Yes, management says operating cash outflows should reduce as revenue builds, margins improve and some prior-quarter obligations fall away. But the fact remains that Memphasys still needs the commercial ramp to accelerate quickly - or more funding to arrive.

There is also the Peters Investments convertible note to consider. The maturity has been extended to 30 June 2026, with an 8 per cent coupon, giving management a little breathing room. Still, "constructive discussions" are comforting only up to a point. Investors will want clarity on how the next leg of growth is funded, and on what terms.

What matters from here

The company has undoubtedly moved the story forward. Revenue is no longer theoretical, repeat orders matter, and regulatory progress in Europe, Australia and India gives the commercial team more territory to work with. Just as importantly, operating costs have been reduced by $57,000 a month, or 22 per cent, as capital is redirected toward manufacturing and commercialisation.

But the market will not reward Memphasys indefinitely for being merely less speculative than it used to be. The next few quarters need to show rising cartridge usage, more active clinics, and customer receipts that start to make the cash burn look less intimidating.

That is the nub of it. Memphasys has finally produced early evidence that Felix can sell. Now it needs to prove the business can scale before the funding treadmill spins faster than the sales cycle.